The Effects of Mixhers HERTIME Supplements on Menstrual Symptoms

Sponsor
Midwestern University (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT06136104
Collaborator
(none)
100
1
2
4.1
24.5

Study Details

Study Description

Brief Summary

The purpose of this study is to assess Mixhers HERTIME supplements efficacy in alleviating menstrual cycle symptoms.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Mixhers HERTIME
  • Dietary Supplement: Placebo
N/A

Detailed Description

All participants, after providing written informed consent, will drink a daily self-administered powder-mix supplement in water of either placebo or Mixhers HERTIME for 120 consecutive days. Surveys will be administered electronically to each participant in the first month to assess baseline menstrual cycle symptoms. In addition, before starting the supplement, participants will take the electronic survey "The Premenstrual Symptoms Screening Tool". During the first month of taking the supplement, participants will take an allergy and constitutional symptom survey electronically to assess for any adverse reactions to the product. Each month for four months, participants will complete an electronic survey assessing menstrual cycle symptoms after a menstrual cycle is completed.

Study Design

Study Type:
Interventional
Actual Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Single Group Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
The Effects of Mixhers HERTIME Supplements on Menstrual Symptoms
Actual Study Start Date :
Aug 30, 2023
Anticipated Primary Completion Date :
Jan 1, 2024
Anticipated Study Completion Date :
Jan 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Mixhers HERTIME

1 daily powder stick packet (3.0-3.3 g) of Mixhers HERTIME herbal supplement mixed into water

Dietary Supplement: Mixhers HERTIME
A daily self-administered powder supplement packet mixed into water.

Placebo Comparator: Placebo

1 daily powder stick packet (3 g) of a matching placebo powder supplement mixed into water

Dietary Supplement: Placebo
A daily self-administered powder placebo supplement packet mixed into water.

Outcome Measures

Primary Outcome Measures

  1. Menstrual Cramping and/or Back Pain [120 days]

    Measured through post-menstrual bleeding electronic survey 1-10 severity scale

  2. Mood Regulation [120 days]

    Measured through post-menstrual bleeding electronic survey 1-10 mood scale

  3. Bloating [120 days]

    Measured through post-menstrual bleeding electronic survey 1-10 severity scale

  4. Menstrual Bleeding Volume [120 days]

    Measured through post-menstrual bleeding electronic survey 1-10 scale of flow volume

  5. Menstrual Bleeding Duration [120 days]

    Measured through post-menstrual bleeding electronic survey recording start and end day of menstrual bleeding

Secondary Outcome Measures

  1. Fatigue [120 days]

    Measured through post-menstrual bleeding electronic survey 1-10 scale of fatigue experienced

  2. Acne [120 days]

    Measured through post-menstrual bleeding electronic survey 1-10 severity scale

  3. Difficulty Concentrating [120 days]

    Measured through post-menstrual bleeding electronic survey 1-10 severity scale

  4. Overeating/Food Cravings [120 days]

    Measured through post-menstrual bleeding electronic survey 1-10 severity scale

  5. Insomnia [120 days]

    Measured through post-menstrual bleeding electronic survey 1-10 severity scale

  6. Hypersomnia [120 days]

    Measured through post-menstrual bleeding electronic survey 1-10 severity scale

  7. Period symptom interference with school/work efficiency/productivity [120 days]

    Measured through post-menstrual bleeding electronic survey four-point Likert scale

  8. Period symptom interference with social life activities [120 days]

    Measured through post-menstrual bleeding electronic survey four-point Likert scale

  9. Period symptom interference with physical activity (sports, gym, or daily performance) [120 days]

    Measured through post-menstrual bleeding electronic survey four-point Likert scale

  10. Any positive or negative mood changes noticed during period [120 days]

    Measured through post-menstrual bleeding electronic survey free response prompt

  11. Any positive or negative mood changes noticed during other weeks of the menstrual cycle not bleeding [120 days]

    Measured through post-menstrual bleeding electronic survey free response prompt

  12. Non-steroidal anti-inflammatory drug use for acute symptoms during menstrual bleeding [120 days]

    Measured through post-menstrual bleeding electronic survey free response prompt

  13. Number of pads/tampons/other products used during menstrual bleeding [120 days]

    Measured through post-menstrual bleeding electronic survey free response prompt

Other Outcome Measures

  1. Other miscellaneous changes noticed during menstrual bleeding [120 days]

    Measured through post-menstrual bleeding electronic survey free response prompt

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 45 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Must be biologically female, must have a regular menstrual cycle (defined as a menstrual bleed every 23-35 days), must be a student, staff, or faculty member at Midwestern University Glendale, Arizona campus
Exclusion Criteria:
  • not pregnant or planning to become pregnant, must not be on anticoagulants, must not have allergies to lemon or stevia

Contacts and Locations

Locations

Site City State Country Postal Code
1 Midwestern University Glendale Arizona United States 85308

Sponsors and Collaborators

  • Midwestern University

Investigators

  • Principal Investigator: Farshad Agahi, MD, Midwestern University- Glendale, AZ

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Midwestern University
ClinicalTrials.gov Identifier:
NCT06136104
Other Study ID Numbers:
  • 23007
First Posted:
Nov 18, 2023
Last Update Posted:
Nov 18, 2023
Last Verified:
Nov 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Midwestern University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 18, 2023